Loading clinical trials...
Loading clinical trials...
A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies
Conditions
Interventions
ALIROCUMAB SAR236553 (REGN727)
placebo (for injection training only)
+4 more
Locations
153
Austria
Investigational Site Number 040001
Graz, Austria
Investigational Site Number 040008
Innsbruck, Austria
Investigational Site Number 040005
Linz, Austria
Investigational Site Number 040006
Linz, Austria
Investigational Site Number 040003
Vienna, Austria
Investigational Site Number 040002
Vienna, Austria
Start Date
June 23, 2015
Primary Completion Date
April 12, 2019
Completion Date
April 12, 2019
Last Updated
March 28, 2022
NCT07473960
NCT00353782
NCT07489209
NCT07058077
NCT06555120
NCT06287177
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions